There is no reliable personal timeline for GHK-Cu. A small eyebrow trial assessed results at 12 weeks; a post-laser skin trial also assessed 12 weeks, with no objective benefit. A nonrandomized scar study followed patients for 16 weeks [1] [3] [2]. These different uses cannot be combined into a universal schedule.
What the one controlled trial measured at 12 weeks
At 12 weeks after CO2 laser resurfacing, blinded evaluators and computer analysis found no significant difference between skin regimens with and without GHK-Cu [3].
The trial randomized patients to a post-laser skin-care routine with or without the copper peptide. Thirteen completed it. Redness didn't clear any faster. Wrinkles and overall skin quality improved in everyone, but not more with GHK-Cu [3].
One thing did differ. On a validated questionnaire at 12 weeks, the GHK-Cu group rated the improvement in their skin quality higher (P = .04) [3]. So people felt a change that the measurements didn't pick up. That's worth knowing, and it's a small study.
| Study | Use | Who, how many | Design | Time point | Finding | Strength of evidence |
|---|---|---|---|---|---|---|
| Bo 2026 [1] | Topical eyebrows | 18 participants | Randomized split-face | 12 weeks | Improved count and diameter; not scalp evidence | Low |
| Vignesh 2026 [2] | Copper peptide plus dermaroller for acne scars | 40 participants | Nonrandomized two-group comparison | 16 weeks | No significant later between-group benefit; pigmentation concern | Low |
| Miller 2006 [3] | Topical, after CO2 laser | 13 completers | Randomized | 12 weeks | No objective difference in redness or wrinkles; users rated skin quality better (P = .04) | Low (tiny trial) |
| Lee 2016 [4] | Scalp, male pattern hair loss | 45 men | Randomized, placebo, 3 arms | 1, 3 and 6 months | Hair count up 52.6 and 71.5 vs 9.6 on placebo at 6 months; length and thickness unchanged. Tested a 5-ALA + GHK blend, not GHK-Cu | Low |
| None found | Injectable GHK-Cu | None | None | None | No controlled human trial | None |
| Najafi 2026 [5] | Systematic review | 64 records | Review | Not applicable | Human evidence "thin and fragmented"; trials small, mostly facial creams | Not applicable |
Where the 4-, 8- and 12-week claims come from
Most published GHK-Cu timelines come from sellers and uncontrolled cosmetic studies, not from adequately powered trials.
A 2026 systematic review screened 1,247 records and kept 64. It found the human literature "thin and fragmented": most randomized trials are small and test facial cosmetic creams [5]. No adequately powered, registered trial of microneedle-delivered GHK-Cu has been published, the review adds.
Much of the mechanism story comes from lab work on wound healing and collagen. An overview is by Loren Pickart, who first isolated the peptide [6]. The 2026 review notes that about 35% of the primary GHK-Cu papers include him or a colleague from his company as an author [5]. Keep that in mind when a timeline cites "the research."
A timeline worth trusting names its study, says how many people were in it, and gives the time point that was actually measured. If a product page can't do all three, read its weeks as a guess. Ask the seller which study the number comes from, and when it was measured.
Topical vs injectable: different products, different evidence
Topical GHK-Cu has a handful of small human cosmetic studies. Injectable GHK-Cu has none published, and FDA flagged it as a compounding safety risk in 2023 [9].
FDA's concern was possible immune reactions from peptide aggregation and impurities, plus limited human safety data [10]. The nominations for injectable GHK-Cu were withdrawn in April 2026, and it isn't on any list that permits compounding. That's why injectable and topical GHK-Cu have different legal status.
So if you've seen "how long does a GHK-Cu injection take to work," the honest answer is that nobody has measured it in people.
Among telehealth programs, AgelessRx, Eden and HealthRX list a compounded topical GHK-Cu cream or foam.
Hair takes longer to judge than skin
Hair studies are usually read at 6 months. The scalp GHK trial used a blend with 5-ALA, while the small eyebrow trial tested GHK-Cu serum at 12 weeks [4].
That trial checked hair at 1, 3 and 6 months and reported its result at 6. Approved hair drugs set similar expectations: the finasteride label says benefit generally takes three months or more of daily use [7]. More on what was actually tested is in GHK-Cu for hair growth.
How to tell whether it's doing anything for you
Photos in the same light, at the start and every few weeks, are the practical way to judge a cosmetic change. A dermatologist can tell you whether the change is real.
- Take a baseline photo before you start, same room, same light, no makeup.
- Compare photos side by side rather than trusting the mirror. The trial above shows how easily feel and measurement part ways.
- If your skin reacts, stop the product and talk to your prescriber or a dermatologist.
- Ask your prescriber what change they'd expect and by when. Your prescriber sets how it's used.
If acne is the goal, the evidence points elsewhere: see GHK-Cu for acne. For skin programs with a lawful route, start with the skin shortlist or the 30-second match.
Where GHK-Cu stands with FDA
GHK-Cu isn't an FDA-approved drug in any form. The non-injectable form is in Category 1 of FDA's 503A list, updated May 14, 2026 [8].
- September 29, 2023: FDA puts GHK-Cu (except injectable routes) in Category 1 and injectable GHK-Cu in Category 2 [9].
- April 22, 2026: the nominations are withdrawn and GHK-Cu comes off both categories; injectable GHK-Cu moves to FDA's "nominated but withdrawn" table [10].
- May 14, 2026: GHK-Cu (except injectable routes) goes back into Category 1 after one nominator clarified it meant to withdraw only the injectable route [8].
- Before the end of February 2027: FDA says it intends to consult its Pharmacy Compounding Advisory Committee on GHK-Cu [8].
Copper-peptide skin care sold as a cosmetic is a separate track. It needs no FDA approval as long as it makes no drug claims [11].